Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 7/20 | 0.39 |
| ▸ | BRD2 | P25440 | 5/20 | 0.39 |
| ▸ | BRD3 | Q15059 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16905852 | 0.84 | CYP3A4 (0.43) | CYP3A4CYP2C9BRD4BRD2BRD3 | |
| SCHEMBL16543574 | 0.79 | HTT (0.47) | CYP3A4MEN1KMT2APKMHTT | |
| SCHEMBL16896875 | 0.78 | LMNA (0.48) | CYP3A4CYP2C9MEN1KMT2APKM | |
| SCHEMBL18949744 | 0.76 | NR3C1 (0.47) | BRD4BRD2BRD3ERN1NR3C1 | |
| SCHEMBL16896857 | 0.75 | NR3C1 (0.45) | CYP3A4CYP2C9MEN1KMT2APKM | |
| SCHEMBL16896861 | 0.75 | BRD4 (0.42) | CYP3A4CYP2C9MEN1KMT2APKM | |
| SCHEMBL18326404 | 0.74 | BRD4 (0.44) | CYP3A4CYP2C9MEN1KMT2APKM | |
| SCHEMBL18359657 | 0.73 | KDM4E (0.57) | CYP3A4BRD4BRD2BRD3ERN1 | |
| SCHEMBL25381719 | 0.73 | PKM (0.43) | MEN1KMT2APKMHTTMAPT | |
| SCHEMBL19422771 | 0.73 | BRD4 (0.45) | CYP3A4CYP2C9BRD4BRD2BRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368906-A1 | BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD1, BRD2, BRD3 | CYP3A4 1942/4885CYP2C9 1528/4885MEN1 2757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.